Replicative immortality is a key feature of
cancer cells and it is maintained by the expression of
telomerase, a promising target of novel
therapies. Long-term
telomerase inhibition can induce resistance, but the mechanisms underlying this process remain unclear. The Sonic hedgehog pathway (SHH) is an embryogenic pathway involved in
tumorigenesis and modulates the transcription of
telomerase. We evaluated the effects of long-term treatment of the
telomerase inhibitor
MST-312 in morphology, proliferation, resistance, and in the SHH pathway molecules expression levels in
lung cancer cells. Cells treated for 12 weeks with
MST-312 showed changes in morphology, such as spindle-shaped cells, and a shift in the distribution of
F-ACTIN from cortical to diffuse. Treatment also significantly reduced cells' efficiency to form spheroids and their clonogenic potential, independently of the cell cycle and telomeric
DNA content. Moreover, GLI-1 expression levels were significantly reduced after 12 weeks of
MST-312 treatment, indicating a possible inhibition of this signaling axis in the SHH pathway, without hindering NANOG and OCT4 expression. Here, we described a novel implication of long-term treatment with
MST-312 functionally and molecularly, shedding new light on the molecular mechanisms of this
drug in vitro.